HC Wainwright Reiterates “Buy” Rating for InflaRx (NASDAQ:IFRX)

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock.

InflaRx Price Performance

NASDAQ:IFRX opened at $1.28 on Friday. InflaRx has a one year low of $1.13 and a one year high of $2.82. The company has a fifty day moving average price of $1.92 and a 200 day moving average price of $1.90. The stock has a market cap of $85.93 million, a P/E ratio of -1.19 and a beta of 1.98.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. As a group, equities research analysts anticipate that InflaRx will post -1.04 EPS for the current year.

Institutional Trading of InflaRx

Institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Securities LLC acquired a new stake in InflaRx during the fourth quarter worth $28,000. Walleye Capital LLC bought a new position in shares of InflaRx during the 4th quarter worth about $51,000. Cubist Systematic Strategies LLC bought a new position in shares of InflaRx during the 4th quarter worth about $55,000. Geode Capital Management LLC boosted its position in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after acquiring an additional 11,900 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after acquiring an additional 19,000 shares during the period. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.